Casopitant

Jump to: navigation, search
Casopitant
Casopitant.png
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC30H35F7N4O2
Molar mass616.26 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Casopitant

Articles

Most recent articles on Casopitant

Most cited articles on Casopitant

Review articles on Casopitant

Articles on Casopitant in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Casopitant

Images of Casopitant

Photos of Casopitant

Podcasts & MP3s on Casopitant

Videos on Casopitant

Evidence Based Medicine

Cochrane Collaboration on Casopitant

Bandolier on Casopitant

TRIP on Casopitant

Clinical Trials

Ongoing Trials on Casopitant at Clinical Trials.gov

Trial results on Casopitant

Clinical Trials on Casopitant at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Casopitant

NICE Guidance on Casopitant

NHS PRODIGY Guidance

FDA on Casopitant

CDC on Casopitant

Books

Books on Casopitant

News

Casopitant in the news

Be alerted to news on Casopitant

News trends on Casopitant

Commentary

Blogs on Casopitant

Definitions

Definitions of Casopitant

Patient Resources / Community

Patient resources on Casopitant

Discussion groups on Casopitant

Patient Handouts on Casopitant

Directions to Hospitals Treating Casopitant

Risk calculators and risk factors for Casopitant

Healthcare Provider Resources

Symptoms of Casopitant

Causes & Risk Factors for Casopitant

Diagnostic studies for Casopitant

Treatment of Casopitant

Continuing Medical Education (CME)

CME Programs on Casopitant

International

Casopitant en Espanol

Casopitant en Francais

Business

Casopitant in the Marketplace

Patents on Casopitant

Experimental / Informatics

List of terms related to Casopitant

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]

See also


References

  1. Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
  2. "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.

Linked-in.jpg